Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 2054

Sort by

Sort Order Select

Journal Articles

Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC

Ahmad Rayes, Brent R. Logan, Xuerong Liu, Jasmeen Dara, Rebecca H. Buckley, Joseph H. Oved, Neena Kapoor, Malika Kapadia, Sharat Chandra, Caridad A. Martinez, Nancy Bunin, Shanmuganathan Chandrakasan, Karin Chen, Jeffrey J Bednarski, Hilary L. Haines, Hesham Eissa, Julie-An M. Talano, Michael D. Keller, Christen L Ebens, Sonali Chaudhury, Evan B. Shereck, Victor M. Aquino, Alan P Knutsen, Jessie L Alexander, Alfred P Gillio, Deepakbabu Chellapandian, Ami J. Shah, Holly K Miller, Mark T Vander Lugt, Christine M. Seroogy, Morna J. Dorsey, Talal Mousallem, Roberta Essom Parrott, Richard J O'Reilly, Paibel I. Aguayo-Hiraldo, Susan E Prockop, Blachy J. Dávila Saldaña, Monica S. Thakar, Lauri M. Burroughs, Troy R. Torgerson, Jennifer W Leiding, Rebecca A Marsh, Linda M Griffith, Michael A. Pulsipher, Donald B. Kohn, Luigi D Notarangelo, Morton J Cowan, Jennifer M Puck, Geoffrey D.E. Cuvelier, Jennifer Heimall, Elie Haddad, Sung-Yun Pai, Christopher C Dvorak

Blood Adv bloodadvances.2025016812.

https://doi.org/10.1182/bloodadvances.2025016812

Published: 2025

Includes: Supplemental data

Journal Articles

Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

David A Sallman, Amy F McLemore, Rami S. Komrokji, Hany Elmariah, Andrew T. Kuykendall, Nelli Bejanyan, Onyee Chan, Rawan Faramand, Joseph A Pidala, Sean J Yoder, Lia E Perez, Taiga Nishihori, Eric Padron, Hugo Fernandez, Jeffrey E. Lancet, Asmita Mishra

Blood Adv bloodadvances.2025017742.

https://doi.org/10.1182/bloodadvances.2025017742

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

Blood Adv bloodadvances.2025017760.

https://doi.org/10.1182/bloodadvances.2025017760

Published: 2025

Includes: Supplemental data

Journal Articles

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

Blood Adv bloodadvances.2025017083.

https://doi.org/10.1182/bloodadvances.2025017083

Published: 2025

Includes: Supplemental data

Journal Articles

Dreaming of a Better Future: Drug Development in Myeloma

Sagar Lonial, Richa Parikh

Blood Adv bloodadvances.2024015740.

https://doi.org/10.1182/bloodadvances.2024015740

Published: 2025

Journal Articles

Deferral of immunosuppression in acquired hemophilia

Jerome Teitel, Jean St-Louis

Blood Adv (2025) 9 (22): 5913–5914.

https://doi.org/10.1182/bloodadvances.2025017953

Published: 2025

Journal Articles

An AI model classifies risks of early relapse post–CAR T-cell therapy in a multicenter real-world population with DLBCL

Michelle Wang, Krishna V. Komanduri, Debajyoti Datta, Ayan Patel, Barbee Whitaker, Artur Belov, Benjamin Rubin, Rohit Vashist, Rosa Rodriguez-Monguio, Pelin Cinar, Steven Anderson, Atul J. Butte

Blood Adv (2025) 9 (22): 5837–5852.

https://doi.org/10.1182/bloodadvances.2025016375

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Inga M. Schimansky, Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul Knöbl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Möhnle, Katharina Holstein, Hermann Eichler, Sonja Werwitzke, Andreas Tiede

Blood Adv (2025) 9 (22): 5853–5860.

https://doi.org/10.1182/bloodadvances.2025017144

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

Blood Adv (2025) 9 (22): 5814–5827.

https://doi.org/10.1182/bloodadvances.2025017214

Published: 2025

Includes: Supplemental data

Journal Articles

Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia

Anna L. Hoppmann, Deborah M. Hurley, Stuart Cramer, Monique J. Brown, Rahul Ghosal, Anthony J. Alberg, Smita Bhatia

Blood Adv (2025) 9 (22): 5861–5869.

https://doi.org/10.1182/bloodadvances.2025017044

Published: 2025

Includes: Supplemental data

Journal Articles

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial

Blood Adv (2025) 9 (22): 5828–5836.

https://doi.org/10.1182/bloodadvances.2025017394

Published: 2025

Includes: Supplemental data

Journal Articles

Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1

Blood Adv (2025) 9 (22): 5752–5762.

https://doi.org/10.1182/bloodadvances.2025016613

Published: 2025

Includes: Supplemental data

Journal Articles

Defining and treating KICS: experience from the largest cohort yet

Casey L. McAtee, Nader Kim El-Mallawany

Blood Adv (2025) 9 (22): 5736–5737.

https://doi.org/10.1182/bloodadvances.2025017869

Published: 2025

Journal Articles

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

Jong Wook Lee, Jun Ho Jang, Hirohito Yamazaki, Masashi Sawa, Masahiro Kizaki, Yoshiaki Tomiyama, Koji Nagafuji, Kensuke Usuki, Jyh-Pyng Gau, Yasuyoshi Morita, Jih-Luh Tang, Hung Chang, Masayoshi Noshiro, Akira Matsuda, Keiya Ozawa, Kinuko Mitani, Yoshinobu Kanda, Shinji Nakao

Blood Adv (2025) 9 (22): 5732–5735.

https://doi.org/10.1182/bloodadvances.2024014855

Published: 2025

Includes: Supplemental data

Journal Articles

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

Blood Adv (2025) 9 (22): 5708–5719.

https://doi.org/10.1182/bloodadvances.2025016949

Published: 2025

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of Kaposi sarcoma herpesvirus–associated inflammatory cytokine syndrome

Ramya Ramaswami, Kathryn Lurain, Mark N. Polizzotto, Anaida Widell, Irene Ekwede, Elena Tassi, Adam Rupert, Vickie A. Marshall, Mark J. Roth, Armando C. Filie, Stefania Pittaluga, Elaine S. Jaffe, Hao-Wei Wang, Denise Whitby, Thomas S. Uldrick, Robert Yarchoan

Blood Adv (2025) 9 (22): 5720–5731.

https://doi.org/10.1182/bloodadvances.2025016685

Published: 2025

Includes: Supplemental data

Journal Articles

A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL

Blood Adv (2025) 9 (21): 5665–5675.

https://doi.org/10.1182/bloodadvances.2025017092

Published: 2025

Includes: Supplemental data

Journal Articles

Double-Hit Lymphoma: Is Lenalidomide Just Right

Jack K. Driml

Blood Adv (2025) 9 (21): 5663–5664.

https://doi.org/10.1182/bloodadvances.2025017787

Published: 2025

Journal Articles

A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis

Blood Adv bloodadvances.2025016845.

https://doi.org/10.1182/bloodadvances.2025016845

Published: 2025

Includes: Supplemental data

Journal Articles

Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials

Soon Jye Kho, Sheila S Diamond, Penelope Lafeuille, Jonathan H Schatz, Francesco Maura, Jacob Aptekar, Frederick L Locke

Blood Adv bloodadvances.2025016361.

https://doi.org/10.1182/bloodadvances.2025016361

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC

Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

Dreaming of a Better Future: Drug Development in Myeloma

Deferral of immunosuppression in acquired hemophilia

An AI model classifies risks of early relapse post–CAR T-cell therapy in a multicenter real-world population with DLBCL

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial

Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1

Defining and treating KICS: experience from the largest cohort yet

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

Characteristics and outcomes of Kaposi sarcoma herpesvirus–associated inflammatory cytokine syndrome

A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL

Double-Hit Lymphoma: Is Lenalidomide Just Right

A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis

Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only